The following mechanism is likely: EZH2 inhibits FOXO1 expression and may serve as a target of EZH2 inhibitors, which can be used to overcome EZH2 inhibitor resistance in PTEN mutant cancers or to treat PTEN-deficient prostate cancer in combination with taxane. The gene discussed is PTEN; the disease is prostate carcinoma.